CytoMed Therapeutics (FRA:F98) Tariff Resilience Score: 7/10 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F98 CytoMed Therapeutics Ltd FRA:F98
19 GF Score
Price €0.76
! 2 Warning Signs
View Full Analysis

What is CytoMed Therapeutics Tariff Resilience Score?

CytoMed Therapeutics FRA:F98 -9.58% 19 Tariff Resilience Score is 7 as of Jul. 25, 2026. GuruFocus rates FRA:F98 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,370 Biotechnology companies, CytoMed Therapeutics ranks better than 90.36% on this metric.

CytoMed Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

CytoMed Therapeutics has Biotech firm with moderate exposure to tariffs on imported research materials. Can mitigate through local suppliers and strategic alliances.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CytoMed Therapeutics might have Highly Resilient.

CytoMed Therapeutics  (FRA:F98) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CytoMed Therapeutics Tariff Resilience Score Related Terms

FRA:F98 vs LEXX, INAB, TRAW: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CytoMed Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoMed Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's Tariff Resilience Score falls into.


FRA:F98
19GF Score
CytoMed Therapeutics Ltd FRA:F98
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
CytoMed Therapeutics (FRA:F98) has a Tariff Resilience Score of 7 as of Jul. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CytoMed Therapeutics ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is CytoMed Therapeutics' Tariff Resilience Score too high?
CytoMed Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. CytoMed Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, CytoMed Therapeutics ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytoMed Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Tariff Resilience Score compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #132 out of 1370 companies for Tariff Resilience Score. This places CytoMed Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CytoMed Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoMed Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoMed Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (FRA:F98) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. CytoMed Therapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CytoMed Therapeutics (FRA:F98), the current Tariff Resilience Score is 7 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoMed Therapeutics Business Description

Other Exchanges GDTC:USA
Address 1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
19GF Score

Get the complete analysis for FRA:F98

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price